Introduction
============

Congenital heart disease (CHD), which defines a large set of structural defects of the heart and intra-thoracic great vessels that occur during embryogenesis, is the most prevalent form of human birth defect worldwide, affecting approximately 1% of live births, with an estimated prenatal incidence of 10 % [@B1]-[@B3]. According to specific anatomic lesions, CHD is clinically categorized into more than 20 distinct types, including ventricular septal defect, atrial septal defect, patent ductus arteriosus, tetraology of Fallot (TOF) and double outlet right ventricle, of which ventricular septal defect is the most common CHD; while TOF is the most common type of cyanotic CHD [@B1]. In addition to degraded quality of life and decreased exercise performance, serious CHD may lead to various complications, including retarded brain development or brain injury, thromboembolism, pulmonary hypertension, chronic heart failure, arrhythmias and sudden cardiac demise [@B4]-[@B16]. Although enormous advancement in the diagnosis and treatment of pediatric CHD has been made during the past 50 years, which allows more than 75% of CHD children to survive into adulthood, unfortunately, it has brought about a growing population of adults living with CHD, with the prevalence of CHD in adults being approximately 3000 per million, and this unique CHD population is increasing by almost 5% per year [@B17],[@B18]. Moreover, these survivors have a significantly increased incidence of late complications and sudden cardiac death [@B18],[@B19]. Obviously, CHD is still associated with substantial morbidity and mortality, and has imposed a heavy socioeconomic burden on patients\' families and societies [@B18],[@B19]. Therefore, reveal of the molecular mechanisms underpinning CHD is of pronounced clinical importance, especially vital to the healthcare of this growing adult CHD community [@B17].

Previous studies have demonstrated that CHD are multi-factorial, with both environmental and genetic risk factors involved in the pathogenesis of CHD [@B17],[@B20],[@B21]. Environmental risk factors for CHD encompass maternal viral infection, drug uses, alcohol consumption, smoking, and exposure to toxic chemicals or ionizing radiation during the first trimester of pregnancy [@B20]. However, epidemiologic studies convincingly suggest that genetic defects are the predominant causes of CHD [@B17],[@B21]. To date, mutations in more than 60 genes have been causally linked to CHD [@B17],[@B21],[@B22]-[@B47]. Among these well-established CHD-causing genes, most code for cardiac transcription factors, including homeodomain-containing transcription factors, zinc-finger transcription factors, and T-box transcription factors [@B17],[@B21],[@B22]-[@B48]. Nevertheless, these known genetic causes of CHD can only explain for less than 20% of all CHD [@B49], and the genetic basis underlying CHD in an overwhelming majority of cases remains unknown.

As a member of the large family of T-box transcription factors, TBX20 have been shown to play a key and dose-sensitive role in cardiovascular genesis. In humans and vertebrate models, TBX20 is amply expressed in the heart throughout cardiac development [@B50]. In mice, TBX20 is abundantly expressed in the heart progenitor cells, cardiomyocytes of the early heart tube and endothelial cells responsible for endocardial cushions, as well as the precursor structures required for the development of cardiac valves and atrioventricular septum [@B51]. Targeted disruption of murine *Tbx20* led to embryonic death, with unlooped and severely hypoplastic myocardial tubes; while heterozygous *Tbx20*-null mice suffered from atrial septal anomalies [@B52]-[@B54]. By contrast, *Tbx20*-knockdown mice exhibited failed septation of the outflow tract, persistent truncus arteriosus and hypoplastic right ventricle [@B55]. Additionally, in zebrafish and *Xenopus*, either loss- or gain-of-function of *Tbx20* resulted in cardiac development abnormalities [@B52]. In humans, mutations in *TBX20* have been associated with atrial septal defect, ventricular septal defect, TOF and double-outlet right ventricle [@B30],[@B31],[@B56]-[@B60]. These findings make it justifiable to screen *TBX20* as a prime candidate gene for CHD in another cohort of patients with CHD.

Materials and methods
=====================

Ethics
------

This study was performed in accordance with the ethical principles of the Declaration of Helsinki. The study protocol was reviewed and approved by the local institutional ethics committee, and written informed consents to the use of the blood samples for genetic analyses were obtained from the study participants or their guardians prior to commencement of this investigation.

Study population
----------------

In this study, a cohort of 175 unrelated patients, who fulfilled the criteria of CHD, was recruited from the Han Chinese population. The available family members of the index patient carrying an identified *TBX20* mutation were also included. A total of 400 unrelated non-CHD individuals from the same geographic area, who were matched to the CHD cases in age, gender and ethnicity, were registered as control subjects. All the study participants were clinically evaluated in detail, including comprehensive individual and medical histories, detailed physical examination, standard 12-lead electrocardiogram, and transthoracic echocardiography with color flow Doppler. Transesophageal echocardiography, cardiac catheter-based procedure or surgery was performed only when there was a strong clinical indication. Various forms of CHD were diagnosed by cardiac ultrasonic imaging and medical records. The patients who were diagnosed with chromosomal abnormalities or syndromic CHD, such as trisomy 13, trisomy 18, trisomy 21, Turner syndrome, Alagille syndrome, Holt-Oram Syndrome and Noonan syndrome, were excluded from the current study. Clinical research was conducted by professionals without knowledge of genotype.

Mutational analysis of TBX20
----------------------------

Peripheral venous blood samples were drawn from all study subjects. Genomic DNA was isolated from whole blood leukocytes using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA) according to the manufacture\'s protocol. The primers to amplify the complete exonic sequences as well as small flanking intronic sequences of *TBX20* by polymerase chain reaction (PCR) were designed as described previously [@B30], and was synthesized commercially (Sangon, Shanghai, China). The total volume of a PCR mixture was 25 μL, comprising 11.25 μL of deionized water, 5 μL of 5× Q solution, 2.5 μL of 10× buffer, 2 μL of dNTPs (2.5 mM each), 1 μL of each primer at 20 μM, 0.25 μL of HotStar Taq DNA Polymerase (Qiagen, Hilden, Germany) at 5 U/μL, and 2 μL of genomic DNA at 200 ng/μL. Typical PCR cycling parameters were predenaturation of template and activation of polymerase at 95 ℃ for 15 minutes, followed by 35 cycles of denaturation at 94 ℃ for 30 seconds, annealing at 62 ℃ for 30 seconds and extension at 72 ℃ for 1 minute, with a final extension at 72 ℃ for 10 minutes. Amplification of genomic DNA was performed in 0.2 ml thin-walled PCR tubes on a GeneAmp PCR System 9700 (Applied Biosystems, Foster, CA, USA). The amplified products were fractionated by electrophoresis on 1.5% agarose gels. After purification with the QIAquick Gel Extraction Kit (Qiagen), both strands of each amplicon were PCR-sequenced with the BigDye^®^ Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) on an ABI PRISM 3130 XL automated DNA analyzer (Applied Biosystems). Resultant sequences were analyzed with a sequence analysis software (Applied Biosystems) and the BLAST program (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>). Whenever a sequence variant was found, the sample was PCR-sequenced again from both forward and reverse directions to confirm the nucleotide change. For a confirmed mutation, its position was based on the complementary DNA reference sequence for *TBX20* (accession no. NM_001077653.2), with the initial codon ATG numbered as residue 1. Additionally, the online databases for human sequence variations, such as the single nucleotide polymorphism (SNP; <http://www.ncbi.nlm.nih.gov/SNP>) database and the human gene mutation (HGM; <http://www.hgmd.org>) database, were queried to confirm its novelty.

Alignment of multiple TBX20 protein sequences across species
------------------------------------------------------------

The amino acid sequences of the TBX20 proteins in human, chimpanzee, monkey, dog, cattle, mouse, fowl, zebrafish and frog were obtained from the GenBank database (<http://www.ncbi.nlm.nih.gov/genbank/>). By using the Clustal Omega software (<http://www.clustal.org/omega/>), multiple alignments of amino acid sequences among these species were performed.

Plasmid constructs and site-directed mutagenesis
------------------------------------------------

The recombinant expression vector TBX20-pcDNA3.1, which contains the full-length cDNA of human *TBX20*, was constructed as previously described [@B30]. The expression plasmids NKX2.5-pEFSA and GATA4-pSSRa as well as the atrial natriuretic factor-luciferase (ANF-luc) reporter construct, which contains the 2600-bp 5\'-flanking region of the *ANF* gene and encodes the Firefly luciferase, were generously provided by Dr. Ichiro Shiojima, at the Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan. With a complementary pair of primers, the identified mutation was introduced into the wild-type TBX20-pcDNA3.1 construct by PCR-based site-directed mutagenesis using the QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The mutant underwent selection by *Dpn*I (TaKaRa, Dalian, China) and was fully sequenced to verify the desired mutation and to exclude any other unwanted sequence variations.

Reporter gene assay of mutant TBX20
-----------------------------------

Chinese hamster ovary (CHO) cells and COS-7 (a fibroblast-like cell line) cells were cultured in Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal calf serum at 37°C in an incubator supplied with 5% CO~2~, and maintained in 12-well plates under standard conditions for 48 hours after transfection. One day before transfection, cells were plated at a density of 2×10^5^ cells/well. The PolyFect Transfection Reagent (Qiagen) was used for transfection of cells according to the manufacturer\'s instructions. The internal control reporter plasmid pGL4.75 (hRluc/CMV, Promega), which expresses Renilla luciferase, was used in transient transfection assays to normalize the trancfection efficiency. Twenty-four hours after plating, CHO cells grown to approximately 90% confluence were transfected with 0.8 μg of wild-type or mutant TBX20-pcDNA3.1 expression vector, 1.0 μg of ANF-luc reporter construct, and 0.04 μg of pGL4.75 control reporter vector. For co-transfection experiments in CHO cells, 0.4 μg of wild-type TBX20-pcDNA3.1 together with 0.4 μg of mutant TBX20-pcDNA3.1 or 0.4 μg of empty pcDNA3.1 vector were used in the presence of 1.0 μg of ANF-luc and 0.04 μg of pGL4.75. For the synergistic activation between TBX20 and NKX2.5 or GATA4 in COS-7 cells, the same amount (0.6 μg) of plasmid (empty pcDNA3.1, wild-type TBX20-pcDNA3.1, NKX2.5-pEFSA, GATA4-pSSRa or K274X-mutant TBX20-pcDNA3.1) was used alone or together, in combination with 1.0 μg of ANF-luc and 0.04 μg of pGL4.75. Transfected cells were washed once on the following day with medium before being refreshed with new medium. Forty-eight hours after transfection, cells were harvested and lysed, and then the Firefly luciferase and Renilla luciferase activities were measured with the Dual-Glo Luciferase Assay Kit (Promega) according to the manufacturer\'s instructions. For promoter activity assays, all experiments were performed at minimum in triplicate and data are reported as the ratio of Firefly luciferase to Renilla luciferase.

Statistical analysis
--------------------

All statistical analyses were carried out with the SPSS for Windows software version 19.0 (SPSS, Chicago, IL, USA). Quantitative data are expressed as means ± standard deviations (SD). Student\'s unpaired *t* test was used to compare quantitative variables between two groups. Comparison of the qualitative variables between two groups was made by using Pearson\'s χ^2^ test or Fisher\'s exact test when appropriate. All reported *p* values were two-tailed and statistical significance was defined as *p* \< 0.05.

Results
=======

Clinical findings
-----------------

A cohort of 175 unrelated patients with CHD underwent a comprehensive clinical evaluation in contrast to a total of 400 unrelated non-CHD control individuals. All the studied patients had echocardiographically or surgically confirmed CHD; while the control subjects had no evidence of congenital defects in cardiovascular structures or positive family history of CHD. None of the study participants had recognized environmental risk factors for CHD, such as maternal viral infection, drug use and long-term exposure to toxic chemicals or ionizing radiation in the first trimester of pregnancy. There is no significant difference in age, gender or ethnicity between patient and control groups. The demographic profiles and clinical features of the CHD patients are summarized in Table [1](#T1){ref-type="table"}.

Identification of a novel TBX20 mutation
----------------------------------------

By sequence analysis of the *TBX20* gene in 175 unrelated patients with CHD, a novel sequence variation was identified in a patient with TOF, who had a positive family history of CHD. Specifically, a substitution of thymine for adenine in the first nucleotide of codon 274 (c.820A\>T), which was predicted to produce a premature stop codon at amino acid position 274 (p.K274X), was identified in the index patient from family A. The sequence chromatograms showing the detected heterozygous *TBX20* mutation and its homozygous control sequence are presented in Figure [1](#F1){ref-type="fig"}A. The schematic diagrams showing the full-length and truncated TBX20 proteins were displayed in Figure [1](#F1){ref-type="fig"}B. The nonsense mutation was absent in the 800 control chromosomes and not found in the SNP and HGM databases (accessed again October 3, 2016). Genetic analysis of the proband\'s available family members showed that his father (I-1), elder brother (II-1) and son (III-3) had also TOF. In addition, his father (I-1) and elder brother (II-1) had also congenital atrial septal defect, presenting with pentalogy of Fallot, and his niece (III-2) had persistent truncus arteriosus and ventricular septal defect. Analysis of the pedigree revealed that the mutation co-segregated with CHD transmitted in an autosomal dominant fashion, with complete penetrance (Figure [1](#F1){ref-type="fig"}C). The phenotypic characteristics and status of TBX20 mutation of the affected family members are reported in Table [2](#T2){ref-type="table"}.

Evolutionary conservation
-------------------------

As shown in Figure [2](#F2){ref-type="fig"}, human TBX20 was aligned with orthologous proteins from multiple species, exhibiting that the altered lysine at amino acid position 274 was highly conserved evolutionarily.

Functional defects of mutant TBX20 in transcriptional activation
----------------------------------------------------------------

As shown in Figure [3](#F3){ref-type="fig"}, the same amount (0.8 μg) of wild-type TBX20 and K274X-mutant TBX20 (K274X) activated the *ANF* promoter by \~11-fold and \~1-fold, respectively. When wild-type TBX20 (0.4 μg) was co-expressed with the same amount (0.4 μg) of K274-mutant TBX20 or empty pcDNA3.1 plasmid, the induced activation of the *ANF* promoter was \~6-fold or \~7-fold. These results indicate that the K274-mutant TBX20 has no transcriptional activity or significantly dominant-negative effect on its wild-type counterpart.

Reduced synergistic activation between TBX20 and NKX2.5 as well as GATA4 by the mutation
----------------------------------------------------------------------------------------

As shown in Figure [4](#F4){ref-type="fig"}, in the presence of NKX2.5, the same amount (0.6 μg) of wild-type TBX20 and K274X-mutant TBX20 (K274X) activated the *ANF* promoter by \~16-fold and \~9-fold, respectively; while in the presence of GATA4, the same amount (0.6 μg) of wild-type TBX20 and K274X-mutant TBX20 (K274X) activated the *ANF* promoter by \~25-fold and \~4-fold, respectively. These data indicate that the mutation diminishes the synergistic activation between TBX20 and NKX2.5 as well as GATA4.

Discussion
==========

In this study, by sequence analysis of the *TBX20* gene, a novel heterozygous mutation, c.820A\>T, which was predicted to generate a truncated protein (p.K274X), was discovered in a family with CHD, including familial TOF and atrial septal defect as well as sporadic persistent truncus arteriosus and ventricular septal defect. In the family, the mutation co-segregated with CHD with complete penetrance. The nonsense mutation was absent in the 800 referral chromosomes from a control population matched in ethnicity and gender. A cross-species alignment of TBX20 proteins showed that the affected amino acid was highly conserved evolutionarily. Biochemical analyses demonstrated that the mutant TBX20 failed to transactivate a target gene. Furthermore, the mutation reduced the synergistic activation between TBX20 and NKX2.5 or between TBX20 and GATA4. Therefore, it is probable that functional failure of TBX20 confers an enhanced susceptibility to CHD in these mutation carriers.

TBX genes encode a large family of transcription factors that are characterized by a highly conserved DNA-binding motif of 180 amino acid residues, T-box. This T-box recognizes a specific DNA element, the T-half site (the consensus DNA sequence of 5-AGGTGTGA-3), that exists singly, or in multiples with different orientation and spacing in the promoters of target genes, and regulates transcriptional activation or inhibition. Moreover, the T-box is also a conserved interaction domain for other transcription factors, chromatin remodelling complexes and histone-modifying enzymes involved in transcriptional mediation [@B50]. In this study, the identified mutation is predicted to yield a truncated protein (p.K274X), losing partial T-box along with the carboxyl terminus, thus may be anticipated to impair the transcriptional function of TBX20 probably by interfering with the specific binding to target genes or the interaction with partners of TBX20.

TBX20 has been demonstrated to transactivate multiple target genes that are expressed in the heart during embryogenesis, including *ANF*, *CX40* and *CX45*, of which *ANF* is the most extensively investigated one, and its expression in the embryonic heart has been established by synergistic action of TBX20, NKX2.5, GATA4 and other transcriptional factors [@B50],[@B51]. In this study, the functional roles of a novel *TBX20* mutation identified in familial TOF patients were evaluated by transcriptional activity assays, and the results revealed no transcriptional activation of the *ANF* promoter by the mutant TBX20 protein, alone or together with NKX2.5 or GATA4. These functional data indicate that haploinsufficiency of TBX20 is potentially an alternative molecular mechanism underpinning TOF.

Previous studies have validated that TBX20 physically interacts with multiple transcription factors, including homeobox transcription factor NKX2.5 and zinc-finger transcription factors GATA4, GATA5 and GATA6, cooperating to synergistically activate the expression of several target genes key to cardiogenesis [@B50],[@B51], and loss-of-function mutations in such transcriptionally cooperative partners as NKX2.5, GATA4, GATA5 and GATA6 have been associated with a wide spectrum of CHD, including atrial septal defect, ventricular septal defect and TOF [@B34],[@B36],[@B37],[@B50]-[@B52],[@B56], which suggest that genetically compromised *TBX20* contributes to CHD probably by diminishing synergistic activation of cardiac core genes with these cooperative partners.

Previously, *TBX20* mutations have been associated with CHD. In fact, so far at least 13 mutations in the coding region of *TBX20* have been identified to be responsible for a great variety of CHD. Kirk *et al*. [@B56] sequenced the whole coding exons of*TBX20* in 353 index patients with CHD, and identified two heterozygous mutations (p.I152M and p.Q195X) in two index patients with familial CHD. Specifically, in family 1 harboring the missense mutation p.I152M, the proband had atrial septal defect; her grandmother had ventricular septal defect, and her mother had patent foramen ovale. In family 2 carrying the nonsense mutation p.Q195X, the proband had atrial septal defect and coarctation of the aorta, and his mother had mitral valve prolapse with mild regurgitation, dilated cardiomyopathy, and apicolateral hypertrophy. Functional deciphers unveiled that I152M-mutant TBX20 had decreased function while Q195X-mutant TBX20 was effectively null. By PCR-sequencing, Qian *et al*. [@B57] screened *TBX20* in 192 unrelated children with CHD, and discovered two mutations in four children, including p.H186D in two children (one child had an atrioventicular canal with secundum and primum atrial septal defects, as well as a cleft mitral valve with moderate mitral regurgitation, and the other child had pentalogy of Fallot) and p.L197P in other two children (one had pentalogy of Fallot and the other had atrial septal defect). However, the functional characteristics of the two mutations were not delineated. Liu *et al*. [@B58] made a sequence analysis of the exons 2 to 6 of *TBX20* in 203 unrelated patients with CHD, and found three non-synonymous mutations of p.A63T, p.I121F and p.T262M in three patients with atrial septal defect, total anomalous pulmonary venous connection and TOF, respectively. However, functional effects of these sequence variants remain to be assayed. Posch *et al*. [@B59] analyzed the entire coding sequences of *TBX20* in 170 unrelated patients with atrial septal defect, and found a novel mutation of p.I121M in a patient with positive family history of CHD. Genetic analysis of the index patient\'s pedigree showed that the mutation co-segregated with CHD in the three-generation kindred. Functional assays showed that the mutation p.I121M resulted in a significantly increased transcriptional activity, which was further increased in the presence of transcription factors GATA4/5 and NKX2.5. By whole-exome sequencing, Liu and colleagues [@B60] analyzed a three-generation family with atrial septal defect, and identified a novel *TBX20* mutation, p.D176N. However, functional analysis of the mutation was not performed. Pan and co-workers [@B30] sequenced the coding exons and flanking introns of the *TBX20* gene in 146 unrelated patients with CHD, and identified a novel heterozygous *TBX20* mutation, p.R143W in an index patient with double outlet right ventricle. Genetic analyses of the proband\'s pedigree showed that the mutation co-segregated with the disease. Biological analysis revealed that mutant TBX20 had a significantly diminished transcriptional activity. By using the high resolution melting and DNA sequencing methods, Monroy-Muñoz and partners [@B31] made a search for *TBX20* mutations in a group of 38 patients with atrial or ventricular septal defect, and found three missense mutations (p.Y309D, p.T370O, and p.M395R) in two patients with atrial septal defect, though functional characterizations of these mutations were not carried out. In the present study, a novel *TBX20* loss-of-function mutation was identified in patients with familial TOF alone or together with familial atrial septal defect, or sporadic persistent truncus arteriosus and ventricular septal defect. Taken collectively, these findings expand the phenotypic spectrum linked to *TBX20* mutations and imply that genetically defective *TBX20* is responsible for CHD in a subset of patients.

In conclusion, this study associates TBX20 loss-of-function mutation with increased vulnerability to TOF or persistent truncus arteriosus in humans for the first time, which provides novel insight into the molecular mechanism of CHD and suggests potential implications for genetic counseling and personalized treatment of the patients with CHD.
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![Novel TBX20 mutation associated with congenital heart disease. (A) Sequence electropherograms showing the TBX20 mutation and its wild-type control. The arrow points to the heterozygous nucleotides of A/T in the proband (mutant) or the homozygous nucleotides of A/A in a control individual (wild type). The rectangle marks the nucleotides comprising a codon of TBX20. (B) Schematic diagrams showing full-length and truncated TBX20 protein structures with the causative mutation marked. The mutation identified in patients with congenital heart disease is predicted to generate a truncated protein with only amino terminus together with partial T-box structural domain left (mutant). NH2, amino terminus; COOH, carboxyl terminus. (C) Pedigree structure of the family with congenital heart disease. The family was designated as family A and the family members are identified by generations and numbers. Square, male family member; circle, female member; symbol with a slash, deceased member; closed symbol, affected member; open symbol, unaffected member; arrow, proband; +, carrier of the heterozygous mutation; -, non-carrier.](ijmsv14p0323g001){#F1}

![Alignment of multiple TBX20 protein sequences across species. The altered lysine at amino acid position 274 (p.K274) of TBX20 is highly conserved evolutionarily among multiple species.](ijmsv14p0323g002){#F2}

![Failure of the mutant TBX20 to transactivate a target gene. Activation of the ANF-luciferase reporter in cultured CHO cells by wild-type TBX20 or K274X-mutant TBX20 (K274X), alone or together, showed that the K274X-mutant TBX20 had no transcriptional activity or significantly inhibitory effect on its wild-type counterpart. Experiments were carried out in triplicate and data were expressed as mean and standard deviations. \* indicates *t* = 5.7200, *p* = 0.0046, and \*\* indicates *t* = 13.5396, *p* = 0.0002, when compared with wild-type TBX20 (0.8 μg).](ijmsv14p0323g003){#F3}

![Abrogated synergistic transactivation between TBX20 and NKX2.5 as well as GATA4. Activation of the ANF-luciferase reporter in cultured COS-7 cells by wild-type TBX20 or K274X-mutant TBX20 (K274X), alone or in combination with NKX2.5 or GATA4, showed that the mutation disrupted the synergistic transactivation between TBX20 and NKX2.5 as well as GATA4. Experiments were performed in triplicate and data were given as mean and standard deviations. \* indicates *t* = 4.2718, *p* = 0.0129, and \*\* indicates *t* = 14.1437, *p* = 0.0001, when compared with their wild-type counterparts.](ijmsv14p0323g004){#F4}

###### 

Demographic profiles and clinical characteristics of the patients with congenital heart disease (n = 175).

  Variables                                                             Statistics
  --------------------------------------------------------------------- ------------
  Male gender (%)                                                       98 (56)
  Female gender (%)                                                     77 (44)
  Age (years)                                                           4.3 ± 3.1
  Positive family history of congenital heart disease (%)               42 (24)
  Clinical classification of congenital heart disease                   
  Isolated congenital heart disease (%)                                 75 (43)
  Ventricular septal defect (%)                                         26 (15)
  Atrial septal defect (%)                                              23 (13)
  Patent ductus arteriosus (%)                                          9 (5)
  Double outlet of right ventricle (%)                                  5 (3)
  Abnormal pulmonary venous connection (%)                              4 (2)
  Truncus arteriosus (%)                                                3 (2)
  Endocardial cushion defect (%)                                        2 (1)
  Hypoplastic left ventricle (%)                                        2 (1)
  Hypoplastic right ventricle (%)                                       1 (1)
  Complex congenital heart disease (%)                                  100 (57)
  Tetralogy of Fallot (%)                                               49 (28)
  Atrial septal defect + ventricular septal defect (%)                  12 (7)
  Ventricular septal defect + patent ductus arteriosus (%)              8 (5)
  Atrial septal defect + tetralogy of Fallot (%)                        7 (4)
  Atrial septal defect + patent ductus arteriosus (%)                   7 (4)
  Double outlet of right ventricle + ventricular septal defect (%)      6 (3)
  Ventricular septal defect + transposition of the great arteries (%)   6 (3)
  Ventricular septal defect + truncus arteriosus (%)                    5 (3)
  Incidence of arrhythmias                                              16 (9)
  Atrioventricular block (%)                                            10 (6)
  Atrial fibrillation (%)                                               6 (3)
  Treatment of congenital heart disease                                 
  Surgical repair (%)                                                   121 (69)
  Catheter-based closure (%)                                            43 (25)
  Follow-up (%)                                                         11 (6)

Data are expressed as means and standard deviations, number or percentage.

###### 

Phenotypic characteristics and TBX20 mutation status of the affected family members.

  Individual   Gender   Age (years)   Cardiac structural defects   TBX20 mutation
  ------------ -------- ------------- ---------------------------- ----------------
  Family A                                                         K274X
  I-1          M        53^a^         TOF, ASD                     NA
  II-1         M        31            TOF, ASD                     +/-
  II-3         M        28            TOF                          +/-
  III-2        F        0             PTA, VSD                     +/-
  III-3        F        2             TOF                          +/-

M, Male; F, female; TOF, tetralogy of Fallot; ASD, atrial septal defect; PTA, persistent truncus arteriosus; VSD, ventricular septal defect; NA, not available; +/-, heterozygote.

^a^Age at death.
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